IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies

Clark, Paul J., Thompson, Alex J. and McHutchison, John G. (2011) IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies. American Journal of Gastroenterology, 106 1: 38-45. doi:10.1038/ajg.2010.370


Author Clark, Paul J.
Thompson, Alex J.
McHutchison, John G.
Title IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies
Journal name American Journal of Gastroenterology   Check publisher's open access policy
ISSN 0002-9270
1572-0241
Publication date 2011
Year available 2011
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1038/ajg.2010.370
Open Access Status
Volume 106
Issue 1
Start page 38
End page 45
Total pages 8
Place of publication New York, NY United States
Publisher Nature Publishing Group
Collection year 2012
Language eng
Subject 2715 Gastroenterology
Abstract Genome-wide association studies (GWAS) have recently identified host genetic variation to be critical for predicting treatment response and spontaneous clearance in patients infected with hepatitis C virus (HCV). These important new studies are reviewed and their future clinical implications discussed. Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)- 3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. The good response variant is associated with a twofold increase in the rate of cure. Allele frequencies differ between ethnic groups, largely explaining the observed differences in response rates between Caucasians, African Americans and Asians. IL28B polymorphism is also strongly associated with spontaneous clearance of HCV. The biological mechanisms responsible for these genetic associations remain unknown and are the focus of ongoing research. Knowledge of a patient's IL28B genotype is likely to aid in clinical decision making with standard of care regimens. Future studies will investigate the possibility of individualizing treatment duration and novel regimens according to IL28B type.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 62 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 77 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 17 Jul 2014, 09:22:38 EST by Anthony Yeates on behalf of Medicine - Princess Alexandra Hospital